Phase 2 Trial to Evaluate Safety and Efficacy of AU-011 Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

• Status: Recruiting
• Trial end date: 2024-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to assess safety and efficacy of AU-011 via suprachoroidal injection to treat primary indeterminate lesions and small choroidal melanoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aura Biosciences

Criteria

Inclusion Criteria:

• Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM)

• Have no evidence of metastatic disease confirmed by imaging

• Be treatment naïve for IL/CM

Exclusion Criteria:

• Have known contraindications or sensitivities to the study drug or laser

• Active ocular disease